CD8A and dengue disease: Since the majority of CD8 T-cell epitopes for the dengue virus are in its non-structural proteins, Dengvaxia® is not expected to elicit a significant T cell-mediated immune response against dengue, which may mean lower overall efficacy compared to other vaccines containing dengue non-structural proteins, though no head-to-head trials are available.